TX
TXMD
TherapeuticsMD, Inc.
$2.12
+0.47%
$24.5M
No data for this timeframe.
Vol
Market Cap$24.5M
Cap SizeNano Cap
Inst. Holders6 funds
Inst. Value$1.0M
Inst. Activity1 buys / 0 sells
SEC Reports3
Recent Activity
May 12, 2026
SEC
TherapeuticsMD reported Q1 2026 results: net income from continuing operations of $103K vs a net loss of $636K in Q1 202
8-K — Impact 4/10
May 11, 2026
earnings_calendar
TXMD Q1 2026 Earnings Scheduled — 2026-05-11
Apr 21, 2026
SEC
TherapeuticsMD reported full-year 2025 financial results showing improved net loss of $(0.7)M (from $(2.3)M in 2024) and
8-K — Impact 5/10
Apr 1, 2026
SEC
This is an amended 10-K filing that corrects minor printer errors in the original filing. The amendment does not change
10-K/A — Impact 5/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
96,500 shares ($157.3K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
35,500 shares ($38.2K)
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 17, 2023 | Cantor Fitzgerald | REITERATE | Neutral → Neutral |
| Jul 13, 2022 | Cantor Fitzgerald | REITERATE | Neutral |
| Jun 7, 2022 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $647.2K | — |
| MORGAN STANLEY | $210.6K | — |
| RENAISSANCE TECHNOLOGIES LLC | $157.3K | DOUBLED |
| FMR LLC | $13.5K | — |
| BANK OF AMERICA CORP | $176.00 | NEAR_EXIT |
6 institutional holders with $1.0M total value (631,208 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, RENAISSANCE. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 397,056 | $647.2K | 62.9% | — |
| 2 | MORGAN STANLEY | 129,217 | $210.6K | 20.5% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 96,500 | $157.3K | 15.3% | DOUBLED +171.8% |
| 4 | FMR LLC | 8,290 | $13.5K | 1.3% | — |
| 5 | BANK OF AMERICA CORP /DE/ | 108 | $176.00 | 0.0% | NEAR_EXIT -79.6% |
| 6 | WELLS FARGO & COMPANY/MN | 37 | $60.00 | 0.0% | TRIM -35.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 35,500 | 96,500 | +171.8% | $157.3K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 14,900 | 35,500 | +138.3% | $38.2K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 4,502 | 362 | -92.0% | $390.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 520 | 106 | -79.6% | $114.00 | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 57 | 37 | -35.1% | $40.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 175 | 4,502 | +2472.6% | $5.2K | 2025-Q2 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 152,802 | 17,400 | -88.6% | $16.1K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 2,012 | 175 | -91.3% | $162.00 | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 97 | 57 | -41.2% | $53.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 11,600 | 152,802 | +1217.3% | $131.4K | 2024-Q4 |
| UBS Group AG | TRIM | 4,847 | 2,012 | -58.5% | $1.7K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 144 | 97 | -32.6% | $83.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 4.7/10.
NEUTRAL
8-K
4/10
TherapeuticsMD reported Q1 2026 results: net income from continuing operations of $103K vs a net los
May 12, 2026
MIXED
8-K
5/10
TherapeuticsMD reported full-year 2025 financial results showing improved net loss of $(0.7)M (from
Apr 21, 2026
BEARISH
10-K/A
5/10
This is an amended 10-K filing that corrects minor printer errors in the original filing. The amendm
Apr 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Aug 2023): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2023-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2023-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
2 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 17, 2023 | Cantor Fitzgerald | REITERATE | Neutral | Neutral |
| Jul 13, 2022 | Cantor Fitzgerald | REITERATE | — | Neutral |
| Jun 7, 2022 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jan 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Dec 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Nov 1, 2023 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
earnings_calendar
TXMD Q1 2026 Earnings Scheduled — 2026-05-11
Mar 25, 2026
earnings_calendar
TXMD Q4 2025 Earnings After Market Close — 2026-03-25